Louis Edward Tamayo - 04 Feb 2026 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Reporting relationship: Chief Financial Officer
Issuer ticker: LXEO
Reported as of: 04 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Feb 2026, 17:00:09 UTC
Prior SEC filing: 03 Sep 2025
Next SEC filing: 01 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Youjin Choi, Attorney-in-Fact

Key filing fact

Louis Edward Tamayo filed Form 4 for Lexeo Therapeutics, Inc. (LXEO) on 06 Feb 2026.

Key facts

This page summarizes Louis Edward Tamayo's Form 4 filing for Lexeo Therapeutics, Inc. (LXEO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Feb 2026, 17:00.

Change

Previous filing in this sequence was filed on 03 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002083206 Primary reporting owner

Tamayo Louis Edward

Relationship: Chief Financial Officer
Address: C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK
Signature: /s/ Youjin Choi, Attorney-in-Fact
Signature date: 06 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LXEO transaction

Common Stock

Award

Transaction value: $0
Shares: +44,665
Change %: +99%
Price: $0.000000
Shares after: 89,665
Date: 04 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LXEO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +226,665
Change %
Price: $0.000000
Shares after: 226,665
Date: 04 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 226,665
Exercise price: $7.27
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.

Footnote F2

The reported securities are RSUs.

Footnote F3

25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.